What is William Blair's Estimate for Moderna Q2 Earnings?

Moderna, Inc. (NASDAQ:MRNA - Free Report) - William Blair lowered their Q2 2025 EPS estimates for Moderna in a note issued to investors on Monday, July 14th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($2.77) for the quarter, down from their prior forecast of ($2.72). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. William Blair also issued estimates for Moderna's FY2026 earnings at ($8.37) EPS.

A number of other research firms also recently weighed in on MRNA. Evercore ISI decreased their price target on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. UBS Group decreased their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Royal Bank Of Canada decreased their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Barclays reissued an "equal weight" rating on shares of Moderna in a research report on Sunday. Finally, Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research report on Sunday. Four equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $46.61.

Moderna Stock Down 1.8%

Shares of MRNA traded down $0.58 during mid-day trading on Wednesday, reaching $31.62. 2,177,767 shares of the stock traded hands, compared to its average volume of 8,891,728. The firm has a market cap of $12.23 billion, a price-to-earnings ratio of -3.64 and a beta of 1.84. The stock has a fifty day simple moving average of $27.77 and a 200 day simple moving average of $31.00. Moderna has a 12-month low of $23.15 and a 12-month high of $126.42.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The business's quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter last year, the firm posted ($3.07) earnings per share.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently modified their holdings of the company. Deutsche Bank AG boosted its holdings in shares of Moderna by 54.7% during the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after acquiring an additional 669,614 shares during the period. Tang Capital Management LLC acquired a new position in shares of Moderna during the fourth quarter valued at $12,474,000. Bank of New York Mellon Corp boosted its holdings in shares of Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after acquiring an additional 34,034 shares during the period. BDF Gestion bought a new stake in shares of Moderna during the first quarter valued at about $783,000. Finally, OVERSEA CHINESE BANKING Corp Ltd raised its stake in shares of Moderna by 73.5% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 40,772 shares of the company's stock valued at $1,156,000 after purchasing an additional 17,268 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.